Sagebrush Inn & Suites Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2018
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Atherosclerosis: Lessons Learned and Concepts Challenged (B2)
Organizer(s) Laura F. Michael, Gerard Pasterkamp and Sekar Kathiresan
February 4—8, 2018
Sagebrush Inn & Suites • Taos, New Mexico USA
Discounted Abstract Deadline: Oct 5, 2017
Abstract Deadline: Nov 7, 2017
Scholarship Deadline: Oct 5, 2017
Discounted Registration Deadline: Dec 7, 2017
Sponsored by Amgen Inc., MedImmune and Novo Nordisk A/S
Summary of Meeting:
Atherosclerosis is a chronic, systemic disease process whereby fatty deposits, inflammation and fibrosis accumulate in arterial vessel walls. Organ systems, including heart, brain and kidneys, as well as extremities, can be damaged, leading to atherosclerosis-driven clinical outcomes. According to the American Heart Association, 15.5 million Americans have coronary heart disease, of which 7.6 million experienced myocardial infarction. These statistics are reflective of global incidence. Treatment of atherosclerosis often begins with robust cholesterol-lowering treatments, yet many patients continue to experience cardiovascular events. Recent attempts to provide cardiovascular protection to such patients have included anti-inflammatory and HDL-raising therapeutic approaches that have yielded little benefit. Building knowledge of atherosclerosis disease etiology, defining unique attributes of patient differences as simple as sex or genetic inheritance, and using technology to identify patients with early disease is foundational for the scientific community to develop urgently needed therapeutics. The current concept of acute coronary syndrome (“the vulnerable plaque”) and widely applied animal models are debated because clinical presentation, underlying pathology and pathogenetic mechanisms are subject to change due to improved medical treatment. The goals of this meeting are to: 1) Challenge current dogma of atherosclerosis etiology and explore intra-organ cross-talk that may underlie disease evolution; 2) Consider emerging risk factors and their origins as intervention targets; and 3) Explore cutting-edge technologies to discover new therapeutic targets and approaches for drug development. By bringing together scientists from preclinical to clinical settings and from industry to academic institutions, this conference will nurture discussions to translate breakthrough discoveries into therapeutics.
View Scholarships/Awards
Atherosclerosis is a chronic, systemic disease process whereby fatty deposits, inflammation and fibrosis accumulate in arterial vessel walls. Organ systems, including heart, brain and kidneys, as well as extremities, can be damaged, leading to atherosclerosis-driven clinical outcomes. According to the American Heart Association, 15.5 million Americans have coronary heart disease, of which 7.6 million experienced myocardial infarction. These statistics are reflective of global incidence. Treatment of atherosclerosis often begins with robust cholesterol-lowering treatments, yet many patients continue to experience cardiovascular events. Recent attempts to provide cardiovascular protection to such patients have included anti-inflammatory and HDL-raising therapeutic approaches that have yielded little benefit. Building knowledge of atherosclerosis disease etiology, defining unique attributes of patient differences as simple as sex or genetic inheritance, and using technology to identify patients with early disease is foundational for the scientific community to develop urgently needed therapeutics. The current concept of acute coronary syndrome (“the vulnerable plaque”) and widely applied animal models are debated because clinical presentation, underlying pathology and pathogenetic mechanisms are subject to change due to improved medical treatment. The goals of this meeting are to: 1) Challenge current dogma of atherosclerosis etiology and explore intra-organ cross-talk that may underlie disease evolution; 2) Consider emerging risk factors and their origins as intervention targets; and 3) Explore cutting-edge technologies to discover new therapeutic targets and approaches for drug development. By bringing together scientists from preclinical to clinical settings and from industry to academic institutions, this conference will nurture discussions to translate breakthrough discoveries into therapeutics.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, February 4 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 8 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 9 in order to fully experience the meeting.
SUNDAY, FEBRUARY 4
MONDAY, FEBRUARY 5
TUESDAY, FEBRUARY 6
WEDNESDAY, FEBRUARY 7
THURSDAY, FEBRUARY 8
FRIDAY, FEBRUARY 9
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, February 4 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 8 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 9 in order to fully experience the meeting.
SUNDAY, FEBRUARY 4
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—11:00
The Natural History of Atherosclerotic Disease
Meeting has ended...abstracts no longer viewable online.
*
Daniel J. Rader,
University of Pennsylvania, USA
Peter Libby,
Brigham and Women's Hospital, USA
Requiem for the Vulnerable Plaque, Challenging Current Concepts
Requiem for the Vulnerable Plaque, Challenging Current Concepts
Sekar Kathiresan,
Verve Therapeutics, USA
Inherited Basis for Myocardial Infarction
Inherited Basis for Myocardial Infarction
Coffee Break
Gerard Pasterkamp,
University Medical Center Utrecht, Netherlands
Geno-Phenotyping of the Vulnerable Plaque and Patient
Geno-Phenotyping of the Vulnerable Plaque and Patient
Philippe Boucher,
University of Strasbourg, France
Short Talk: Wnt5a Decreases mTORC1/SREBP2 Activity and Promotes Endosomal Cholesterol Trafficking to the ER in Mice and in Human Vascular Smooth Muscle Cells
Short Talk: Wnt5a Decreases mTORC1/SREBP2 Activity and Promotes Endosomal Cholesterol Trafficking to the ER in Mice and in Human Vascular Smooth Muscle Cells
Sumeet A. Khetarpal,
University of Pennsylvania, USA
Short Talk: A Human APOC3 Missense Variant and Monoclonal Antibody Accelerate apoC-III Clearance and Lower Triglyceride-rich Lipoprotein Levels
Short Talk: A Human APOC3 Missense Variant and Monoclonal Antibody Accelerate apoC-III Clearance and Lower Triglyceride-rich Lipoprotein Levels
14:30—16:30
Workshop 1
*
Ira G. Schulman,
University of Virginia Health System, USA
Liam Brunham,
University of British Columbia, Canada
Genetic Regulation of HDL Cholesterol Levels during Sepsis
Genetic Regulation of HDL Cholesterol Levels during Sepsis
Ruchi Gupta,
MedImmune/AstraZeneca, USA
LOX-1: The Cause of and Solution to Inflammation and Lipid Accumulation in Atherosclerosis
LOX-1: The Cause of and Solution to Inflammation and Lipid Accumulation in Atherosclerosis
Anna Kerstin Emy Hultgardh,
Lund University, Sweden
IL-22 Deficiency Reduces Formation of Advanced Atherosclerotic Carotid Plaques in ApoE-Deficient Mice
IL-22 Deficiency Reduces Formation of Advanced Atherosclerotic Carotid Plaques in ApoE-Deficient Mice
Ashok Kumar Kumawat,
Orebro University, Sweden
Targeting IL-6/IL17A in Vascular Inflammation using Affibody Molecules
Targeting IL-6/IL17A in Vascular Inflammation using Affibody Molecules
Mulugeta Melkie Zegeye,
Orebro University, Sweden
Activation of JAK/STAT3 and PI3K Pathways Are Crucial for MCP-1 Induction by IL6 Trans-Signaling in Human Endothelial Cells
Activation of JAK/STAT3 and PI3K Pathways Are Crucial for MCP-1 Induction by IL6 Trans-Signaling in Human Endothelial Cells
Sean Allen,
Northwestern University, USA
Targeted Inhibition of NF-κB in Mouse Models of Atherosclerosis Results in Sex-Dependent Immunomodulation
Targeted Inhibition of NF-κB in Mouse Models of Atherosclerosis Results in Sex-Dependent Immunomodulation
Anna Mathew,
University of Michigan, USA
Myeloperoxidase-Derived Oxidants Damage Artery Wall Proteins in an Animal Model of Chronic Kidney Disease-Accelerated Atherosclerosis
Myeloperoxidase-Derived Oxidants Damage Artery Wall Proteins in an Animal Model of Chronic Kidney Disease-Accelerated Atherosclerosis
17:00—19:00
Lipoprotein Risk Factors
Meeting has ended...abstracts no longer viewable online.
*
Laura F. Michael,
Eli Lilly and Company, USA
Kiran Musunuru,
University of Pennsylvania, USA
Therapeutic Genome Editing as a Cure for Atherosclerosis
Therapeutic Genome Editing as a Cure for Atherosclerosis
Anne Tybjærg-Hansen,
Copenhagen University Hospital, Denmark
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights from Epidemiology, Genetics, and Biology
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights from Epidemiology, Genetics, and Biology
Daniel J. Rader,
University of Pennsylvania, USA
Functionalizing HDL Cholesterol
Functionalizing HDL Cholesterol
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Diabetes, Obesity and Atherosclerosis
Meeting has ended...abstracts no longer viewable online.
*
Siddhartha Jaiswal,
Stanford University, USA
J. Mark Brown,
Cleveland Clinic, USA
Selective Small Molecule Inhibition of Gut Microbial Enzymes for the Treatment of Cardiometabolic Disorders
Selective Small Molecule Inhibition of Gut Microbial Enzymes for the Treatment of Cardiometabolic Disorders
Joerg Heeren,
University Medical Center Hamburg-Eppendorf, Germany
Protective Role of Brown Adipose in Atherosclerosis Development
Protective Role of Brown Adipose in Atherosclerosis Development
Coffee Break
Laura F. Michael,
Eli Lilly and Company, USA
Diabetes and Atherosclerosis: Anti-Diabetic Agents that Improve Cardiovascular Outcomes
Diabetes and Atherosclerosis: Anti-Diabetic Agents that Improve Cardiovascular Outcomes
Robert C. Bauer,
Columbia University, USA
Short Talk: Adipose Knockout of Tribbles-1, a GWAS Locus for Coronary Artery Disease, Reduces Plasma Lipids and Increases Circulating Adiponectin
Short Talk: Adipose Knockout of Tribbles-1, a GWAS Locus for Coronary Artery Disease, Reduces Plasma Lipids and Increases Circulating Adiponectin
Brian Parks,
University of Wisconsin-Madison, USA
Journal of Lipid Research Junior Investigator Award: Short Talk: Leveraging Mouse Liver Co-Expression Networks and Human Lipid GWAS Data to Identify and Validate Cholesterol Metabolism Genes
Journal of Lipid Research Junior Investigator Award: Short Talk: Leveraging Mouse Liver Co-Expression Networks and Human Lipid GWAS Data to Identify and Validate Cholesterol Metabolism Genes
17:00—19:00
The Inflammation Hypothesis
Meeting has ended...abstracts no longer viewable online.
*
Katey Rayner,
University of Ottawa, Canada
Ziad Mallat,
University of Cambridge, UK
Immune Modulation in Atherosclerosis
Immune Modulation in Atherosclerosis
Jan Nilsson,
Lund University, Sweden
Autoimmunity, Injury and Repair as Potential Targets for Intervention in Atherosclerosis
Autoimmunity, Injury and Repair as Potential Targets for Intervention in Atherosclerosis
Paul M. Ridker,
Brigham and Women's Hospital, Harvard Medical School, USA
Anti-inflammatory Therapies for Chronic Atherosclerosis
Anti-inflammatory Therapies for Chronic Atherosclerosis
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
The Milieu Exterieur
Meeting has ended...abstracts no longer viewable online.
*
Gerard Pasterkamp,
University Medical Center Utrecht, Netherlands
Salim Yusuf,
McMaster University, Canada
How Can We Reduce Premature CVD Globally in a Generation?
How Can We Reduce Premature CVD Globally in a Generation?
Sudha B. Biddinger,
Boston Children's Hospital, Harvard Medical School, USA
Beyond Hyperglycemia: Novel Mediators of Diabetes-Associated Cardiovascular Disease
Beyond Hyperglycemia: Novel Mediators of Diabetes-Associated Cardiovascular Disease
Coffee Break
Seppo Yla-Herttuala,
University of Eastern Finland, Finland
Epigenetics, VEGFs and Noncoding RNAs in Atherosclerosis and Angiogenesis
Epigenetics, VEGFs and Noncoding RNAs in Atherosclerosis and Angiogenesis
Robert E. Gerszten,
Beth Israel Deaconess Medical Center, USA
Translating Exercise into Reduced Atherosclerosis Burden
Translating Exercise into Reduced Atherosclerosis Burden
Brian Bennett,
US Department of Agriculture, USA
Short Talk: Genetic and MicroRNA Association with the Cardiometabolic Disease Risk Factor TMAO
Short Talk: Genetic and MicroRNA Association with the Cardiometabolic Disease Risk Factor TMAO
Michael C. Petriello,
University of Kentucky, USA
Short Talk: Serum Levels of Dioxin-Like Pollutants Are Positively Associated with the Cardiometabolic Disease Risk Biomarker Trimethylamine-N-oxide in Leaner Individuals
Short Talk: Serum Levels of Dioxin-Like Pollutants Are Positively Associated with the Cardiometabolic Disease Risk Biomarker Trimethylamine-N-oxide in Leaner Individuals
14:30—16:30
Workshop 2
*
Dominique P.V. de Kleijn,
University Medical Center Utrecht, Netherlands
Camilla Gustafsen,
Aarhus University, Denmark
Heparan Sulfate Proteoglycans Present PCSK9 to the LDL Receptor
Heparan Sulfate Proteoglycans Present PCSK9 to the LDL Receptor
Fan E. Mo,
National Cheng Kung University, Taiwan
CCN1 and Its Receptor Integrin alpha6beta1 Instigate a Vicious Circle to Accelerate Disturbed Flow-Induced Atherosclerosis
CCN1 and Its Receptor Integrin alpha6beta1 Instigate a Vicious Circle to Accelerate Disturbed Flow-Induced Atherosclerosis
Andrew J. Morris,
University of Kentucky, USA
Functional Validation of PPAP2B Gene Variants as Determinants of Coronary Artery Disease Risk
Functional Validation of PPAP2B Gene Variants as Determinants of Coronary Artery Disease Risk
Edward R. O'Brien,
University of Calgary, Canada
Natural Antibodies to HSP27 Are Novel Biomarkers for Cardiovascular Health: HSP27 Immunization Attenuates PCSK9 Transcription and Atherogenesis
Natural Antibodies to HSP27 Are Novel Biomarkers for Cardiovascular Health: HSP27 Immunization Attenuates PCSK9 Transcription and Atherogenesis
Ira G. Schulman,
University of Virginia Health System, USA
Regulation of HDL Function and Inflammation by Liver X Receptors
Regulation of HDL Function and Inflammation by Liver X Receptors
Tapan Shah,
Rutgers New Jersey Medical School, USA
Sex Specific Differences in Post-Transcriptional Gene Regulation of BMP2 in Cardiovascular Calcification
Sex Specific Differences in Post-Transcriptional Gene Regulation of BMP2 in Cardiovascular Calcification
Vincent J. Venditto,
University of Kentucky, USA
Anti-ApoA-I Antibody Profiles Predict Cardiovascular Disease Outcomes in Patients and in a Mouse Model of Atherosclerosis
Anti-ApoA-I Antibody Profiles Predict Cardiovascular Disease Outcomes in Patients and in a Mouse Model of Atherosclerosis
Hong Yang,
Meharry Medical College, USA
Upregulation of ABCA1 Transcription and Inhibition of ABCA1 Protein Degradation by VLDLR/apoER2 Pathway
Upregulation of ABCA1 Transcription and Inhibition of ABCA1 Protein Degradation by VLDLR/apoER2 Pathway
17:00—19:15
Crosstalk Among Organs
Meeting has ended...abstracts no longer viewable online.
*
Jan Nilsson,
Lund University, Sweden
Viktoria Gusarova,
Regeneron Pharmaceuticals, USA
ANGPTL3 Blockade as a Therapeutic Approach for Treatment of Dyslipidemia and Atherosclerosis
ANGPTL3 Blockade as a Therapeutic Approach for Treatment of Dyslipidemia and Atherosclerosis
Lilach O. Lerman,
Mayo Clinic, USA
New Concepts in Atherosclerotic Renovascular Disease: Current Status
New Concepts in Atherosclerotic Renovascular Disease: Current Status
Joachim Herz,
University of Texas Southwestern Medical Center, USA
Multitasking Therapeutics: What Brain Development, Alzheimer’s Disease and Atherosclerosis Have in Common
Multitasking Therapeutics: What Brain Development, Alzheimer’s Disease and Atherosclerosis Have in Common
Johan Lars Markus Björkegren,
Icahn School of Medicine at Mount Sinai, USA
Cardiometabolic Risk Loci Share Downstream Cis- and Trans-Gene Regulation Across Tissues and Diseases
Cardiometabolic Risk Loci Share Downstream Cis- and Trans-Gene Regulation Across Tissues and Diseases
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Keynote Address
Meeting has ended...abstracts no longer viewable online.
*
Sekar Kathiresan,
Verve Therapeutics, USA
Jesper Gromada,
Regeneron Pharmaceuticals, USA
PCSK9 and ANGPTL3 Inhibitors: A New Era of Lipid-Lowering Therapies
PCSK9 and ANGPTL3 Inhibitors: A New Era of Lipid-Lowering Therapies
09:00—11:15
Models and Biomarkers for Atherosclerotic Disease
Meeting has ended...abstracts no longer viewable online.
*
Viktoria Gusarova,
Regeneron Pharmaceuticals, USA
Jacob Fog Bentzon,
Centro Nacional de Investigaciones Cardiovasculares, Spain
Gene-Modified Minipigs: Applications in Atherosclerosis Imaging
Gene-Modified Minipigs: Applications in Atherosclerosis Imaging
Coffee Break
Lesca Miriam Holdt,
University Hospital, LMU Munich, Germany
Circular RNA in Atherosclerosis
Circular RNA in Atherosclerosis
Katey Rayner,
University of Ottawa, Canada
New Inflammatory Drivers and Biomarkers of Atherosclerosis
New Inflammatory Drivers and Biomarkers of Atherosclerosis
Kelsey E. Jarrett,
Baylor College of Medicine, USA
Short Talk: Somatic Genome Editing of Ldlr with AAV-CRISPR Is a Rapid Method for Atherosclerosis Investigation
Short Talk: Somatic Genome Editing of Ldlr with AAV-CRISPR Is a Rapid Method for Atherosclerosis Investigation
14:30—16:30
Workshop 3
*
Thomas Beyer,
Eli Lilly and Company, USA
Maria Ines Azambuja,
Universidade Federal do Rio Grande do Sul, Brazil
The Information that We Need to Advance Knowledge on Atherogenesis Exists and It Is Stored as Levels and Trends of Mortality over the Last Century: Influenza is the Key to Retrieve It
The Information that We Need to Advance Knowledge on Atherogenesis Exists and It Is Stored as Levels and Trends of Mortality over the Last Century: Influenza is the Key to Retrieve It
Dominique P.V. de Kleijn,
University Medical Center Utrecht, Netherlands
Diagnosis of Atherosclerotic Coronary Heart Disease using Plasma Extracellular Vesicle Proteins
Diagnosis of Atherosclerotic Coronary Heart Disease using Plasma Extracellular Vesicle Proteins
Trine Pagh Ludvigsen,
Novo Nordisk A/S, Denmark
Effect of Statin Treatment Compared to Dietary Cessation on Aortic Plaque Size and Inflammation in a Diet-Induced Atherosclerotic Göttingen Minipig Model
Effect of Statin Treatment Compared to Dietary Cessation on Aortic Plaque Size and Inflammation in a Diet-Induced Atherosclerotic Göttingen Minipig Model
Ananthi Rajamoorthi,
St. Louis University School of Medicine, USA
Therapeutic Silencing of CIDEC/Fsp27 Is Atheroprotective in Ldlr-/- Mice
Therapeutic Silencing of CIDEC/Fsp27 Is Atheroprotective in Ldlr-/- Mice
Divya Sagar,
MedImmune, USA
Soluble LOX-1: A Potential Biomarker for SLE and Cardiovascular Comorbidity
Soluble LOX-1: A Potential Biomarker for SLE and Cardiovascular Comorbidity
James Wingrove,
CardioDx, USA
The Added Value of a Multi-Omics Approach for the Evaluation of Patients with Suspected Obstructive Coronary Artery Disease
The Added Value of a Multi-Omics Approach for the Evaluation of Patients with Suspected Obstructive Coronary Artery Disease
Jifeng Zhang,
University of Michigan, USA
Attenuated Atherosclerosis in Human Apolipoprotein A-II knockin Rabbits
Attenuated Atherosclerosis in Human Apolipoprotein A-II knockin Rabbits
17:00—18:45
Emerging Fields of Research
Meeting has ended...abstracts no longer viewable online.
*
Sekar Kathiresan,
Verve Therapeutics, USA
Marlys L. Koschinsky,
Western University, Canada
Lipoprotein(a): Ready for Prime Time?
Lipoprotein(a): Ready for Prime Time?
Hester den Ruijter,
University Medical Center, Utrecht, Netherlands
Sex Differences in Cardiovascular Disease
Sex Differences in Cardiovascular Disease
Siddhartha Jaiswal,
Stanford University, USA
Clonal Hematopoiesis in Aging and Atherosclerotic Cardiovascular Disease
Clonal Hematopoiesis in Aging and Atherosclerotic Cardiovascular Disease
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
19:30—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
